Latest Share Chat

IN BRIEF: Shield Therapeutics says Feraccru approved in Australia

Tue, 09th Mar 2021 14:18

Shield Therapeutics PLC - commercial stage pharmaceutical company - notes that Australia's Therapeutics Goods Administration has approved Feraccru to treat iron deficiency with or without anaemia in adults. Feraccru is already approved in the UK, EU, Switzerland and US. Norgine Pty Ltd will lead all marketing activities in Australia, Shield Therapeutics noted.

Current stock price: 38.95 pence, down 0.8% on Tuesday

Year-to-date change: down 37%

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Related Shares

More News

30 Apr 2024 19:54

EARNINGS AND TRADING: Software Circle & Beximco report higher revenue

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reporte...

23 Apr 2024 14:26

UK earnings, trading statements calendar - next 7 days

21 Feb 2024 16:57

LONDON MARKET CLOSE: FTSE 100 takes hit ahead of FOMC minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors anxiously look ahead to this evening's Federal Open Market Committee ...

21 Feb 2024 12:36

Shield Therapeutics sinks as strong performance marred by data issues

(Alliance News) - Shield Therapeutics PLC on Wednesday said that it was expecting stellar results for 2023, but this success was overshadowed by a mis...

9 Jan 2024 11:33

IN BRIEF: Shield Therapeutics hires former Akili leader as new CFO

Shield Therapeutics PLC - Commercial-stage pharmaceutical company focused on iron deficiency product Accrufer - Hires Santosh Shanbhag as chief financ...